RecruitingNCT06520111

CRISAL Study:Cancer Risk In Secreting Adrenal Lesions

Sponsor

University of Roma La Sapienza

Enrollment

300 participants

Start Date

Aug 27, 2024

Study Type

OBSERVATIONAL

Conditions

Surgery Adrenal Incidentaloma Adrenal Tumor

Summary

The aim of the present study is to report the cancer risk in secreting adrenal lesions. Secondary aims: to compare the incidence of cancer in secreting versus non-secreting adrenal lesions, in order to evaluate whether adrenal hormone activity can be considered an independent predictive indicator of malignancy; compare intraoperative and 30-day postoperative outcomes of patients undergoing adrenalectomy for secreting adrenal lesions versus non-secretoring lesions; regardless of the type of adrenal lesion, identify if there is one MIS adrenal approach that is superior to the others in terms of intra- and postoperative outcomes.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This registry study is collecting data on patients having surgery to remove an adrenal gland (the small gland that sits on top of the kidney), to study whether hormone-secreting adrenal tumors are linked to a higher risk of cancer. **You may be eligible if...** - You are 18 or older - You are scheduled for planned (non-emergency) adrenal gland removal surgery - You are willing to sign informed consent **You may NOT be eligible if...** - You are having emergency adrenal surgery - You are under 18 - You are pregnant Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.